Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of EEC for diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and older
ChiCTR2500097480Phase 3Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of EEC in Tuberculosis (TB) (6 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Sensitivity of EEC versus EC in tuberculosis patients aged 3 to 64 years, Specificity of EEC versus EC in non-tuberculous lung disease patients aged 3 to 64 years and 4 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
EEC
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2500097480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097480.